Acetylation as an indicator of risk

Environmental Health Perspectives

Volumn 105, Issue SUPPL. 4, 1997, Pages 763-766

  Lang, Nicholas P ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE   (United States)

Author keywords

Acetylation; Biomarker; NAT1; NAT2; Phenotyping; Risk assessment

Indexed keywords

AROMATIC AMINE; CARCINOGEN;

ACETYLATION; BLADDER CANCER; CANCER RISK; COLON CANCER; CONFERENCE PAPER; DETOXIFICATION; DRUG ACTIVATION; ENZYME SPECIFICITY; GENOTYPE; HUMAN; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; XENOBIOTIC METABOLISM;

EID: 0030770435     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.97105s4763     Document Type: Conference Paper

References (44)

1. Weber WW, Cohen SN. The mechanism of isoniazid acetylation by human N-acetyltransferase. Biochim Biophys Acta 151:276-278 (1968).
2. Weber WW, Vatsis KP. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics 3:209-212 (1993).
3. Ohsako S, Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J Biol Chem 265:4630-4634 (1990).
4. Vatsis KP, Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 301:71-76 (1993).
5. Hickman D, Sim E. N-acetyltransferase polymorphism. Biochem Pharmacol 42:1007-1014 (1991).
6. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 2:842-845 (1982).
7. Burgess EJ, Trafford JA. Acetylator phenotype in patients with lung carcinoma - a negative report. Eur J Respir Diseases 67:17-19 (1985).
8. Lang NP, Chu DZ, Hunter CF, Kendall DC, Flammang TJ, Kadlubar FF. Role of aromatic amine acetyltransferase in human colorectal cancer. Arch Surg 121:1259-1261 (1986).
9. Ilett KF, David BM, Detchon P, Castleden WM, Kwa R. Acetylation phenotype in colorectal carcinoma. Cancer Res 47:1466-1469 (1987).
10. Lang NP, Butler MA, Massengill J, Lawson M, Stotts RC et al. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev 3:675-682 (1994).
11. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, Elder J, Hendrickse C, Duncan H, Strange RC. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 55:3537-3542 (1995).
12. Agundez JA, Ladero JM, Olivera M, Abildua R, Roman JM, Benitez J. Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients. Oncology 52:7-11 (1995).
13. Ambrosone CB, Freudenheim JL, Marshall JR, Graham S, Vena JE, Brasure JR, Harrington AM, Shields PG. Premenopausal breast cancer risk, smoking, body mass index (BMI) and NAT2. In: Proceedings of the 87th Annual Meeting, of the American Association for Cancer Research, 1996, Washington, DC. A1778. Linthicum, MD:Cadmus Journal Services, 1996;261.
14. Ilett KF, Ingram DM, Carpenter DS, Teitel CH, Lang NP, Kadlubar FF, Minchin RF. Expression of monomorphic and polymorphic N-acetyltransferases in human colon. Biochem Pharmacol 47:914-917 (1994).
15. Derewlany LO, Knie B, Koren G. Human placental transfer and metabolism of p-aminobenzoic acid. J Pharmacol Exp Ther 269:761-765 (1994).
16. Cribb AE, Grant DM, Miller MA, Spielberg SP. Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes. J Pharmacol Exp Ther 259:1241-1246 (1991).
17. Turesky RJ, Lang NP, Butler MA, Teitel CH, Kadlubar FF. Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis 12:1839-1845 (1991).
18. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, Grant DM. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14:1633-1638 (1993).
19. Flammang TJ, Yamazoe Y, Guengerich FP, Kadlubar FF. The S-acetyl coenzyme A-dependent metabolic activation of the carcinogen N-hydroxy-2-aminofluorene by human liver cytosol and its relationship to the aromatic amine N-acetyltransferase phenotype. Carcinogenesis 8:1967-1970 (1987).
20. Kadlubar FF. Carcinogenic aromatic amine metabolism and DNA adduct detection in humans. In: Proceedings of the Princess Takamatsu Symposium, Tokyo, Japan. 21:329-338 (1990).
21. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveille C, Shields PG, Skipper P, Talaska G et al. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 369:154-156 (1994).
22. Bartsch H, Caporaso N, Coda M, Kadlubar F, Malaveille C, Skipper P, Talaska G, Tannenbaum SR, Vineis P. Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. J Natl Cancer Inst 82:1826-1831 (1990).
23. 32P-postlabelling. Chem Res Toxicol 7:733-739 (1994).
24. Evans WE, Relling MV, Petros WP, Meyer WH, Mirro JJ, Crom WR. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 45:568-573 (1989).
25. Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 4:125-134 (1994).
26. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 33:591-602 (1983).
27. Kalow W. Caffeine and other drugs. [Review]. Prog Clin Biol Res 214:331-341 (1986).
28. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 37:25-79 (1985).
29. Hanson A, Melander A, Wahlin-Boll E. Acetylator phenotyping: a comparison of the isoniazid and dapsone tests. Eur J Clin Pharmacol 20:233-4 (1981).
30. Grant DM, Tang BK, Kalow W. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 33:355-359 (1983).
31. Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ, Jollow HR, Keiser HR. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 18:70-9 (1975).
32. Goel UC, Bajaj S, Gupta OP, Dwivedi NC, Dubey AL. Isoniazid induced neuropathy in slow versus rapid acetylators: an electrophysiological study [Comments]. J Assoc Physicians India 40:671-2 (1992).
33. Gutmann L, Martin JD, Welton W. Dapsone motor neuropathy - an axonal disease. Neurology 26:514-516 (1976).
34. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2:116-127 (1992).
35. Mashimo M, Suzuki T, Abe M, Deguchi T. Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum Genet 90:139-143 (1992).
36. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 14:1689-1692 (1993).
37. Cribb AE, Isbrucker R, Levatte T, Tsui B, Gillespie CT, Renton KW. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity. Pharmacogenetics 4:166-170 (1994).
38. Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 55:5230-7 (1995).
39. Wolf H, Lower GM Jr, Bryan GT. Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines. Scand J Urol Nephrol 14:161-165 (1980).
40. Mommsen S, Aagaard J. Susceptibility in urinary bladder cancer: acetyltransferase phenotypes and related risk factors. Cancer Lett 32:199-205 (1986).
41. Hirvonen A, Nylund L, Kociba P, Husgafvel-Pursiainen K, Vainio H. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers Carcinogenesis 15:813-815 (1994) [published erratum appears in Carcinogenesis 15(8):1767 (1994)].
42. Vineis P, Schulte PA. Scientific and ethical aspects of genetic screening of workers for cancer risk: the case of the N-acetyltransferase phenotype. J Clin Epidemiol 48:189-197 (1995).
43. Dewan A, Chattopadhyay P, Kulkarni PK. N-acetyltransferase activity - a susceptibility factor in human bladder carcinogenesis. Indian J Cancer 32:15-19 (1995).
44. Wong P, Leyland-Jones B, Wainer IW. A competitive enzyme linked immunosorbent assay for the determination of N-acetyltransferase (NAT2) phenotypes. J Pharmacol Biomed Anal 13:1079-1086 (1995).